Submitted:
15 October 2026
Posted:
20 October 2026
You are already at the latest version
Abstract
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by amyloid-β (Aβ) accumulation, pathological tau aggregation, and neuronal loss. Neuroinflammation is increasingly recognized as a contributor to disease progression, with microglia playing a central and context-dependent role. This mini-review examines the reciprocal interactions between microglia and neuroinflammation in AD, focusing on Aβ handling, inflammatory signaling, and tau pathology. We discuss how microglia may support pathological protein clearance while also promoting inflammatory responses through pathways involving NF-κB, the NLRP3 inflammasome, and oxidative stress–TRPM2 signaling. We further explore how microglial processing of tau may either limit its accumulation or facilitate its propagation. These findings highlight the dual role of microglia in AD, functioning as both protective responders and potential drivers of neuroinflammation and neurodegeneration.
Keywords:
Alzheimer’s disease
; microglia
; neuroinflammation
; amyloid-β
; tau
; NLRP3 inflammasome
1. Introduction
Alois Alzheimer first described Alzheimer’s disease (AD) as a “peculiar disease process in the cerebral cortex” in 1906 (Hippius & Neundörfer, 2003). Later on, Emil Kraeplin first termed the disease as AD in 1910 (Hippius & Neundörfer, 2003). AD is the most common neurodegenerative disorder and a leading cause of dementia in older adults (Butts & Haut, 2023). It is characterized clinically by progressive cognitive decline and pathologically by the accumulation of amyloid-β plaques, neurofibrillary tangles containing hyperphosphorylated tau, synaptic dysfunction, and neuronal loss (Crews & Masliah, 2010; Iqbal & Grundke-Iqbal, 2002; Knowles et al., 1999; Scheff, Price, Schmitt, DeKosky, & Mufson, 2007). Although amyloid-β and tau pathology remain central features of AD, accumulating evidence indicates that these pathological changes alone do not fully explain the complexity and heterogeneity of disease progression. Increasing attention has therefore been directed toward neuroimmune mechanisms, particularly chronic inflammation within the central nervous system, as important contributors to AD pathogenesis (Calsolaro & Edison, 2016; Leng & Edison, 2021).
Among the cellular components of the neuroimmune system, microglia are increasingly recognized as key regulators of the inflammatory environment in the AD brain. As the resident immune cells of the central nervous system, microglia continuously monitor their microenvironment and contribute to synaptic remodeling, clearance of cellular debris, and maintenance of neuronal homeostasis. In response to pathological stimuli such as amyloid-β accumulation, damaged neurons, and altered extracellular signals, microglia undergo substantial functional and phenotypic changes. These responses may initially serve protective functions by promoting the clearance of pathological material and limiting tissue damage. However, persistent or dysregulated microglial activation can promote the production of pro-inflammatory mediators, disrupt synaptic function, impair amyloid-β clearance, and contribute to neuronal injury.
Importantly, microglial activation and neuroinflammation are not merely an independent process. Rather, they interact through a complex and reciprocal network of cytokines, chemokines, complement components, lipid mediators, and other signaling pathways. Genetic studies have further strengthened the link between microglial biology and AD risk by identifying variants in immune-related genes, including TREM2, CD33, and CR1, that influence susceptibility to disease (Jansen et al., 2019). These findings suggest that alterations in microglial function may affect not only the response to established AD pathology but also the development and progression of neurodegeneration.
Thus, microglia may represent both a protective response to pathological stress and a potential driver of chronic neuroinflammation, depending on the cellular environment, disease stage, and nature of the underlying stimulus. Understanding the factors that determine this transition from protective to potentially detrimental microglial activity is therefore critical for developing effective therapeutic strategies. In this mini-review, we examine the reciprocal interactions between microglial responses and neuroinflammation in AD, focusing on the dual roles of microglia in amyloid-β (Aβ) handling, inflammatory signaling, and tau pathology.
2. Neuroinflammation in Alzheimer’s Disease
Neuroinflammation is a complex and context-dependent process involving coordinated responses of resident and infiltrating immune cells within and around the central nervous system. Although the term is widely used to describe inflammatory responses in the brain and spinal cord, its precise definition remains challenging because neuroinflammatory responses can vary considerably depending on the initiating stimulus, disease state, and cellular environment (Ransohoff, 2016). Neuroinflammation can be triggered by diverse pathological insults, including infection, tissue injury, ischemia, and neurodegenerative processes, and may involve interactions between central and peripheral immune signaling pathways.
Under physiological conditions, inflammatory responses serve important protective functions by detecting pathological stimuli, promoting clearance of damaged material, and supporting tissue repair. However, when these responses are sustained or inadequately resolved, inflammation can become maladaptive. Chronic neuroinflammation has been increasingly implicated in neurodegenerative disorders, including AD, where persistent inflammatory signaling may contribute to synaptic dysfunction, neuronal injury, and progressive neurodegeneration (Calsolaro & Edison, 2016; Heneka et al., 2015) (Leng and Edison, 2021).
In AD, pathological stimuli including Aβ accumulation, tau pathology, neuronal injury, and cellular debris can activate innate immune responses within the brain. Activated immune cells can subsequently release cytokines and chemokines including TNF-α, IL-1β, IL-6, and CCL-family chemokines, as well as reactive oxygen and nitrogen species, complement components, and other inflammatory mediators that influence neuronal and synaptic function (DiSabato, Quan, & Godbout, 2016). Although these responses may initially promote the clearance of pathological material and protect neural tissue, prolonged or dysregulated inflammatory signaling can instead contribute to synaptic damage, impaired neuronal function, and disease progression. Thus, neuroinflammation in AD should not be viewed as uniformly detrimental; rather, its effects may depend on the intensity, duration, cellular phenotype, and stage of disease.
Among the cellular components involved in this process, microglia are particularly important because they serve as the principal resident immune cells of the central nervous system. Microglia continuously survey the neural environment and respond to changes in tissue homeostasis, including the accumulation of pathological proteins such as Aβ and abnormal tau species, as well as signals associated with neuronal injury. Their ability to initiate, amplify, and resolve inflammatory responses places microglia at the intersection between protective neuroimmune responses and chronic pathological inflammation. Understanding how microglial responses shape, and are shaped by, the inflammatory environment is therefore essential for determining whether microglia exert predominantly protective or pathogenic effects during AD progression.
3. Microglia: The Resident Immune Cells of the CNS
Microglia are the principal resident immune cells of the central nervous system (CNS) and play essential roles in maintaining the neural microenvironment. Unlike neurons and macroglial cells, microglia are derived from primitive myeloid progenitors originating in the embryonic yolk sac and populate the developing CNS early in embryogenesis (Alliot, Godin, & Pessac, 1999; Ginhoux et al., 2010; Ginhoux, Lim, Hoeffel, Low, & Huber, 2013). Following their establishment within the CNS, microglia develop into highly specialized immune cells that continuously survey the surrounding neural environment and respond to changes in tissue homeostasis.
In the healthy adult brain, microglia are predominantly maintained in a homeostatic state characterized by a highly ramified morphology and dynamic surveillance of the surrounding tissue. Rather than being inactive, homeostatic microglia continuously extend and retract their processes to monitor neuronal activity and the extracellular environment. They contribute to several essential physiological processes, including neuronal survival, synaptic remodeling and pruning, clearance of cellular debris, and maintenance of tissue homeostasis. These functions highlight that microglia are not simply immune cells that become relevant only during disease; they are integral components of normal brain function.
Microglia are highly responsive to pathological or physiological changes within the CNS. In response to signals associated with infection, tissue injury, protein accumulation (Aβ and abnormal tau species), neuronal dysfunction, or other forms of cellular stress, microglia undergo substantial changes in morphology, gene expression, metabolism, and functional state. Historically, these responses were often described as a transition from “homeostatic” ramified microglia to an “activated” amoeboid phenotype (Kaur & Ling, 1991; Nayak, Roth, & McGavern, 2014). However, accumulating evidence indicates that microglial responses are considerably more heterogeneous and dynamic than this binary classification suggests (Paolicelli et al., 2022). Depending on the nature, intensity, and duration of the stimulus, microglia can adopt functional states that support tissue protection and repair or, conversely, contribute to chronic inflammation and neuronal injury (Eggen & Kooistra, 2026).
This functional duality is particularly relevant to AD. In response to Aβ accumulation, tau pathology, damaged neurons, and other disease-associated signals, microglia can promote the recognition and clearance of pathological material and initially limit tissue damage. However, persistent stimulation may lead to maladaptive microglial responses characterized by sustained inflammatory signaling, oxidative stress, altered phagocytic function, and disruption of neuronal and synaptic homeostasis. Activated microglia can release a range of inflammatory mediators, including cytokines and chemokines, (including IL-1β, TNF-α, IL-8) reactive oxygen and nitrogen species, and other signaling molecules that can influence neighboring microglia and neural cells (Bernath, Murray, Yang, Gibon, & Klegeris, 2023; Biswas, 2023; Lindhout, Murray, Richards, & Klegeris, 2021; Steinert & Amal, 2023). Consequently, microglial activation can establish a self-reinforcing inflammatory environment in which microglial responses and neuroinflammation amplify one another. This dual role places microglia at the center of the protective or pathogenic concept in AD. Microglia may initially function as protective responders that maintain tissue integrity and facilitate the removal of pathological material, but persistent or dysregulated responses may transform these same functions into drivers of chronic neuroinflammation, synaptic dysfunction, and neurodegeneration. Understanding the mechanisms that determine this transition is therefore critical to understanding the contribution of microglia to AD pathogenesis
4. Microglia–Neuroinflammation Interactions in Alzheimer’s Disease
Microglia participate in both the containment of AD pathology and the inflammatory processes that contribute to neuronal injury. Aβ, pathological tau, and neuronal damage can activate microglia, while microglial responses can influence Aβ and tau accumulation, synaptic function, and neuronal survival (Heneka et al., 2015; Leng & Edison, 2021; Maphis et al., 2015). Thus, the central question is therefore not whether microglia are beneficial or harmful, but how their responses to pathological stimuli can support tissue maintenance in some circumstances and promote disease progression in others.
4.1. Aβ–Microglia Interaction: From Protective Clearance to Chronic Inflammation
Aβ accumulation is one of the earliest pathological features of AD and can precede the appearance of clinical symptoms by many years (Villemagne et al., 2013). Aβ peptides are generated through sequential cleavage of amyloid precursor protein by β- and γ-secretases and can subsequently aggregate into oligomeric and fibrillar species that accumulate within the brain (Walker, 2020). Although Aβ deposition is a defining pathological feature of AD, its accumulation also represents an important stimulus for the innate immune system.
Microglia can be recruited and accumulated around Aβ deposits, where they can recognize and internalize Aβ through multiple receptor-mediated mechanisms. Experimental studies have implicated Toll-like receptors (TLRs), including TLR2 and TLR4, and the co-receptor CD14 in microglial responses to Aβ. For instance, TLR2 stimulation can enhance microglial Aβ uptake by upregulating formyl peptide receptor 2 (FPR2), an Aβ-binding receptor, while CD14, TLR2, and TLR4 contribute to phagocytic responses elicited by fibrillar Aβ (Chen et al., 2006; Reed-Geaghan, Savage, Hise, & Landreth, 2009). Moreover, evidence from an Alzheimer’s disease mouse model further suggests that TLR2 can contribute to Aβ clearance and limit cognitive decline (Richard, Filali, Préfontaine, & Rivest, 2008). These findings support a protective role for microglial recognition and handling of pathological Aβ, although uptake alone does not establish complete degradation or effective clearance. However, Aβ recognition through TLR2 can also initiate pro-inflammatory signaling and the production of inflammatory mediators (Jana, Palencia, & Pahan, 2008). Thus, microglial responses to Aβ may support its removal while simultaneously promoting inflammation, with the net effect depending on the signaling pathways engaged and the surrounding disease environment.
Persistent exposure to Aβ, however, can alter microglial function and promote a sustained inflammatory response. As Aβ pathology progresses, microglial phagocytic and metabolic functions may become dysregulated, while inflammatory signaling becomes increasingly prominent. As such, chronic inflammation leads to the release of a variety of proinflammatory cytokines, chemokines, and toxic by-products including reactive oxygen species (ROS) and nitric oxide (NO), which intensify immunological reactions leading to neurotoxicity (Kinney et al., 2018). Consequently, a response that initially serves a protective function may contribute to chronic neuroinflammation and neuronal dysfunction (Heneka et al., 2015; Leng and Edison, 2021).
Beyond their role in plaque-associated responses, microglia may also contribute to the dissemination of Aβ pathology. Experimental studies suggest that microglia can transport Aβ material into previously unaffected brain tissue, while microglia-derived microvesicles and ASC specks may promote the propagation or aggregation of Aβ (d’Errico et al., 2022; Joshi et al., 2014; Venegas & Heneka, 2017). Hence, it can induce a widespread pathology in multiple loci in the brain. Once deposited and chronically exposed, Aβ plaque may also act as a damage-associated molecular pattern (DAMP) and bind to various receptors such as toll-like receptors (TLRs), nucleotide-binding oligomerization domain-like receptors (NLRs), and receptors for advanced glycation end products (RAGE). A consequence of Aβ plaque binding to those receptors is the activation of the surrounding microglia and astrocytes, resulting in the release of numerous cytokines and chemokines (including IL-6, IL-1β, IFN-γ, TNF-α, IL-8R, TLR-4) and subsequently recruiting more and more microglial cells to the Aβ locus (Heneka, Kummer, & Latz, 2014). Taken together, microglia can participate in Aβ handling while simultaneously contributing to an inflammatory environment that compromises neuronal function and may lead to cognitive dysfunction in AD.
4.2. Microglial Inflammatory Signaling and Amplification
Several intracellular pathways link pathological recognition to sustained microglial inflammation. Among these, nuclear factor-κB (NF-κB) signaling and the NLRP3 inflammasome have received considerable attention in AD pathology. NF-κB signaling promotes inflammatory gene expression, whereas activation of the NLRP3 inflammasome leads to caspase-1 activation and maturation of inflammatory cytokines, particularly interleukin-1β (IL-1β) (Heneka et al., 2013). These mechanisms connect Aβ-associated signals with inflammatory responses that can contribute to neuronal and synaptic dysfunction when persistently activated.
Oxidative stress provides an additional mechanism of inflammatory amplification. In cultured microglia, Aβ42 stimulates ROS production through protein kinase C (PKC)- and NADPH oxidase (NOX)-dependent mechanisms. ROS promotes activation of poly (ADP-ribose) polymerase-1 (PARP-1), leading to activation of the transient receptor potential melastatin 2 (TRPM2) channel, a redox-sensitive, calcium-permeable cation channel (Huang, Winkler, Sun, Lü, & Du, 2018; Jiang, Li, Mortadza, Lovatt, & Yang, 2018). TRPM2-mediated Ca²⁺ influx engages downstream PYK2 and MEK/ERK signaling, which can further reinforce PARP-1 and TRPM2 activation. Importantly, genetic deletion or pharmacological inhibition of TRPM2 attenuated Aβ42-induced microglial activation and tumor necrosis factor-α (TNF-α) production, supporting a functional role for this pathway in Aβ-associated inflammatory responses (Alawieyah Syed Mortadza, Sim, Neubrand, & Jiang, 2018). These findings identify a potential positive-feedback mechanism linking oxidative stress, calcium signaling, and microglial inflammation, although the evidence comes primarily from experimental cell models and does not, by itself, establish the extent to which this pathway drives disease progression in human AD.
The consequences of sustained microglial inflammatory signaling extend beyond microglia themselves. Pro-inflammatory cytokines, chemokines, ROS, nitric oxide, and other mediators released during chronic activation can alter neuronal excitability, impair synaptic function, promote oxidative and metabolic stress, and contribute to neuronal injury. In addition, inflammatory signaling can modify astrocyte function and influence other components of the neurovascular and immune environment. Therefore, microglia can function not only as responders to pathological stimuli but also as amplifiers of the inflammatory environment in the AD brain (Heneka et al., 2015; Leng & Edison, 2021). Nevertheless, inflammatory activation is only one aspect of microglial function. Their roles in pathological protein (Aβ and tau) handling and tissue maintenance underscore why indiscriminate suppression of microglia may be undesirable; therapeutic strategies must distinguish damaging inflammatory pathways from functions that support neural integrity.
4.3. Microglia–Tau Interaction
Pathological tau is closely associated with neuronal dysfunction and clinical progression in AD. Experimental studies indicate that pathological tau can activate microglia and alter the expression of genes associated with phagocytic and inflammatory functions (Morales, Jiménez, Mancilla, & Maccioni, 2013; Wes et al., 2014). Microglia may also shape tau pathology through their handling of extracellular tau species. Although the uptake and degradation of tau seeds could limit their persistence and potential spread, internalization alone does not ensure effective degradation. Thus, the influence of microglia on tau pathology may depend not only on their capacity to engulf extracellular tau but also on their ability to process and eliminate it. Asai et al. (2015) demonstrated that microglial depletion reduced tau propagation in a mouse model and provided evidence implicating microglial exosome secretion in this process (Asai et al., 2015). This finding illustrates how the processing of pathological material can have opposing consequences: microglial uptake may contribute to clearance, whereas subsequent release of tau-containing extracellular vesicles may facilitate its spread. The balance between these outcomes, and their relative importance in human AD, requires further investigation. The microglia–tau relationship therefore extends beyond inflammatory activation. Microglia can influence the handling and dissemination of pathological tau, linking immune responses to the progression of protein pathology. Whether these interactions constrain or facilitate disease progression depends partly on the fate of the internalized tau and the inflammatory environment in which processing occurs.
5. Conclusions
Microglia play a complex and context-dependent role in AD, participating in both protective responses and processes that contribute to neurodegeneration. As discussed in this mini-review, microglia can recognize and handle Aβ, yet persistent exposure to pathological stimuli may promote inflammatory signaling and oxidative stress. Similarly, microglial interactions with tau may influence both its clearance and propagation. These findings highlight that the beneficial and detrimental effects of microglia are not necessarily mutually exclusive but may coexist depending on the cellular environment and the nature of the pathological stimulus. Therefore, understanding how microglia balance protein handling, inflammatory responses, and tissue maintenance is essential for clarifying their contribution to AD progression. This knowledge may ultimately help guide therapeutic strategies that limit maladaptive inflammation while preserving the physiological functions of microglia.
Acknowledgments
American Heart Association and Autism Speaks Postdoctoral Fellowship (Grant No. 26POST1552813) to KG and American Heart Association Career Development Award (Grant No. 26CDA161847) to RKR.
Conflicts of Interest
None.
Generative AI statement
OpenAI ChatGPT (GPT-5.5 Thinking; OpenAI, San Francisco,CA, USA) was used only for limited language editing and clarity improvement of author-generated text. The tool was not used to generate original scientific content, modify and generate references, or draw scientific conclusions. All AI-assisted edits were reviewed and approved by the authors, who take full responsibility for the accuracy and integrity of the manuscript.
References
- Alawieyah Syed Mortadza, S.; Sim, J. A.; Neubrand, V. E.; Jiang, L. H. A critical role of TRPM2 channel in Aβ42-induced microglial activation and generation of tumor necrosis factor-α. Glia 2018, 66(3), 562–575. [Google Scholar] [CrossRef] [PubMed]
- Alliot, F.; Godin, I.; Pessac, B. Microglia derive from progenitors, originating from the yolk sac, and which proliferate in the brain. Developmental Brain Research 1999, 117(2), 145–152. [Google Scholar] [CrossRef] [PubMed]
- Asai, H.; Ikezu, S.; Tsunoda, S.; Medalla, M.; Luebke, J.; Haydar, T.; Ikezu, T. Depletion of microglia and inhibition of exosome synthesis halt tau propagation. Nature Neuroscience 2015, 18(11), 1584–1593. [Google Scholar] [CrossRef] [PubMed]
- Bernath, A. K.; Murray, T. E.; Yang, S. S.; Gibon, J.; Klegeris, A. Microglia secrete distinct sets of neurotoxins in a stimulus-dependent manner. Brain Research 2023, 1807, 148315. [Google Scholar] [CrossRef] [PubMed]
- Biswas, K. Microglia mediated neuroinflammation in neurodegenerative diseases: A review on the cell signaling pathways involved in microglial activation. Journal of Neuroimmunology 2023, 578180. [Google Scholar] [CrossRef] [PubMed]
- Butts, A. M.; Haut, M. W. Introductory editorial to the special issue: Alzheimer’s disease biomarkers and cognitive functioning along the Alzheimer’s continuum. Aging, Neuropsychology, and Cognition 2023, 30(6), 861–865. [Google Scholar] [CrossRef] [PubMed]
- Calsolaro, V.; Edison, P. Neuroinflammation in Alzheimer’s disease: current evidence and future directions. Alzheimer’s & Dementia 2016, 12(6), 719–732. [Google Scholar] [CrossRef] [PubMed]
- Chen, K.; Iribarren, P.; Hu, J.; Chen, J.; Gong, W.; Cho, E. H.; Wang, J. M. Activation of Toll-like receptor 2 on microglia promotes cell uptake of Alzheimer disease-associated amyloid β peptide. Journal of Biological Chemistry 2006, 281(6), 3651–3659. [Google Scholar] [CrossRef] [PubMed]
- Crews, L.; Masliah, E. Molecular mechanisms of neurodegeneration in Alzheimer’s disease. Human Molecular Genetics 2010, 19(R1), R12–R20. [Google Scholar] [CrossRef] [PubMed]
- d’Errico, P.; Ziegler-Waldkirch, S.; Aires, V.; Hoffmann, P.; Mezö, C.; Erny, D.; Joseph, K. Microglia contribute to the propagation of Aβ into unaffected brain tissue. Nature Neuroscience 2022, 25(1), 20–25. [Google Scholar] [CrossRef] [PubMed]
- DiSabato, D. J.; Quan, N.; Godbout, J. P. Neuroinflammation: the devil is in the details. Journal of Neurochemistry 2016, 139, 136–153. [Google Scholar] [CrossRef] [PubMed]
- Eggen, B. J.; Kooistra, S. M. Microglial states revisited: from homeostasis to disease. Nature Reviews Neuroscience 2026, 1–11. [Google Scholar]
- Ginhoux, F.; Greter, M.; Leboeuf, M.; Nandi, S.; See, P.; Gokhan, S.; Stanley, E. R. Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science 2010, 330(6005), 841–845. [Google Scholar] [CrossRef] [PubMed]
- Ginhoux, F.; Lim, S.; Hoeffel, G.; Low, D.; Huber, T. Origin and differentiation of microglia. Frontiers in cellular neuroscience 2013, 7, 45. [Google Scholar] [CrossRef] [PubMed]
- Heneka, M. T.; Carson, M. J.; El Khoury, J.; Landreth, G. E.; Brosseron, F.; Feinstein, D. L.; Ransohoff, R. M. Neuroinflammation in Alzheimer’s disease. The Lancet Neurology 2015, 14(4), 388–405. [Google Scholar] [PubMed]
- Heneka, M. T.; Kummer, M. P.; Latz, E. Innate immune activation in neurodegenerative disease. Nature Reviews Immunology 2014, 14(7), 463–477. [Google Scholar] [CrossRef] [PubMed]
- Heneka, M. T.; Kummer, M. P.; Stutz, A.; Delekate, A.; Schwartz, S.; Vieira-Saecker, A.; Tzeng, T.-C. NLRP3 is activated in Alzheimer’s disease and contributes to pathology in APP/PS1 mice. Nature 2013, 493(7434), 674–678. [Google Scholar] [CrossRef] [PubMed]
- Hippius, H.; Neundörfer, G. The discovery of Alzheimer’s disease. Dialogues in Clinical Neuroscience 2003, 5(1), 101–108. [Google Scholar] [PubMed]
- Huang, Y.; Winkler, P. A.; Sun, W.; Lü, W.; Du, J. Architecture of the TRPM2 channel and its activation mechanism by ADP-ribose and calcium. Nature 2018, 562(7725), 145–149. [Google Scholar] [CrossRef] [PubMed]
- Iqbal, K.; Grundke-Iqbal, I. Neurofibrillary pathology leads to synaptic loss and not the other way around in Alzheimer disease. Journal of Alzheimer’s Disease 2002, 4(3), 235–238. [Google Scholar] [CrossRef] [PubMed]
- Jana, M.; Palencia, C. A.; Pahan, K. Fibrillar amyloid-β peptides activate microglia via TLR2: implications for Alzheimer’s disease. The Journal of Immunology 2008, 181(10), 7254–7262. [Google Scholar] [CrossRef] [PubMed]
- Jansen, I. E.; Savage, J. E.; Watanabe, K.; Bryois, J.; Williams, D. M.; Steinberg, S.; Athanasiu, L. Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer’s disease risk. Nature Genetics 2019, 51(3), 404–413. [Google Scholar] [CrossRef] [PubMed]
- Jiang, L.-H.; Li, X.; Mortadza, S. A. S.; Lovatt, M.; Yang, W. The TRPM2 channel nexus from oxidative damage to Alzheimer’s pathologies: An emerging novel intervention target for age-related dementia. Ageing Research Reviews 2018, 47, 67–79. [Google Scholar] [CrossRef] [PubMed]
- Joshi, P.; Turola, E.; Ruiz, A.; Bergami, A.; Libera, D.; Benussi, L.; Legname, G. Microglia convert aggregated amyloid-β into neurotoxic forms through the shedding of microvesicles. Cell Death and Differentiation 2014, 21(4), 582–593. [Google Scholar] [CrossRef] [PubMed]
- Kaur, C.; Ling, E. Study of the transformation of amoeboid microglial cells into microglia labelled with the isolectin Griffonia simplicifolia in postnatal rats. Acta Anatomica 1991, 142(2), 118–125. [Google Scholar] [CrossRef] [PubMed]
- Kinney, J. W.; Bemiller, S. M.; Murtishaw, A. S.; Leisgang, A. M.; Salazar, A. M.; Lamb, B. T. Inflammation as a central mechanism in Alzheimer’s disease. Alzheimer’s & Dementia: Translational Research & Clinical Interventions 2018, 4, 575–590. [Google Scholar] [CrossRef] [PubMed]
- Knowles, R. B.; Wyart, C.; Buldyrev, S. V.; Cruz, L.; Urbanc, B.; Hasselmo, M. E.; Hyman, B. T. Plaque-induced neurite abnormalities: implications for disruption of neural networks in Alzheimer’s disease. Proceedings of the National Academy of Sciences 1999, 96(9), 5274–5279. [Google Scholar] [CrossRef] [PubMed]
- Leng, F.; Edison, P. Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here? Nature Reviews Neurology 2021, 17(3), 157–172. [Google Scholar] [CrossRef] [PubMed]
- Lindhout, I. A.; Murray, T. E.; Richards, C. M.; Klegeris, A. Potential neurotoxic activity of diverse molecules released by microglia. Neurochemistry International 2021, 148, 105117. [Google Scholar] [CrossRef] [PubMed]
- Maphis, N.; Xu, G.; Kokiko-Cochran, O. N.; Jiang, S.; Cardona, A.; Ransohoff, R. M.; Bhaskar, K. Reactive microglia drive tau pathology and contribute to the spreading of pathological tau in the brain. Brain 2015, 138(6), 1738–1755. [Google Scholar] [CrossRef] [PubMed]
- Morales, I.; Jiménez, J. M.; Mancilla, M.; Maccioni, R. B. Tau oligomers and fibrils induce activation of microglial cells. Journal of Alzheimer’s Disease 2013, 37(4), 849–856. [Google Scholar] [CrossRef] [PubMed]
- Nayak, D.; Roth, T. L.; McGavern, D. B. Microglia development and function. Annual Review of Immunology 2014, 32, 367–402. [Google Scholar] [CrossRef] [PubMed]
- Paolicelli, R. C.; Sierra, A.; Stevens, B.; Tremblay, M.-E.; Aguzzi, A.; Ajami, B.; Bennett, M. Microglia states and nomenclature: A field at its crossroads. Neuron 2022, 110(21), 3458–3483. [Google Scholar] [CrossRef] [PubMed]
- Ransohoff, R. M. How neuroinflammation contributes to neurodegeneration. Science 2016, 353(6301), 777–783. [Google Scholar] [CrossRef] [PubMed]
- Reed-Geaghan, E. G.; Savage, J. C.; Hise, A. G.; Landreth, G. E. CD14 and toll-like receptors 2 and 4 are required for fibrillar Aβ-stimulated microglial activation. The Journal of neuroscience 2009, 29(38), 11982–11992. [Google Scholar] [CrossRef] [PubMed]
- Richard, K. L.; Filali, M.; Préfontaine, P.; Rivest, S. Toll-like receptor 2 acts as a natural innate immune receptor to clear amyloid β1–42 and delay the cognitive decline in a mouse model of Alzheimer’s disease. The Journal of neuroscience 2008, 28(22), 5784–5793. [Google Scholar] [CrossRef] [PubMed]
- Scheff, S. W.; Price, D. A.; Schmitt, F. A.; DeKosky, S.; Mufson, E. J. Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment. Neurology 2007, 68(18), 1501–1508. [Google Scholar] [CrossRef] [PubMed]
- Steinert, J. R.; Amal, H. The contribution of an imbalanced redox signalling to neurological and neurodegenerative conditions. Free Radical Biology and Medicine 2023, 194, 71–83. [Google Scholar] [CrossRef] [PubMed]
- Venegas, C.; Heneka, M. T. Danger-associated molecular patterns in Alzheimer’s disease. Journal of Leucocyte Biology 2017, 101(1), 87–98. [Google Scholar] [CrossRef] [PubMed]
- Villemagne, V. L.; Burnham, S.; Bourgeat, P.; Brown, B.; Ellis, K. A.; Salvado, O.; Maruff, P. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease: a prospective cohort study. The Lancet Neurology 2013, 12(4), 357–367. [Google Scholar] [CrossRef] [PubMed]
- Walker, L. C. Aβ plaques. Free neuropathology 2020, 1. [Google Scholar] [PubMed]
- Wes, P. D.; Easton, A.; Corradi, J.; Barten, D. M.; Devidze, N.; DeCarr, L. B.; Polson, C. Tau overexpression impacts a neuroinflammation gene expression network perturbed in Alzheimer’s disease. PloS One 2014, 9(8), e106050. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.